Sugi Predict

Sugi Predict / Compounds / SCHEMBL20570922

SCHEMBL20570922

SCHEMBL20570922

CC(C)(C)OC(=O)N1CCC(Oc2ccc(Cl)c(Br)c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 5/20 0.56
▸ HRH3 Q9Y5N1 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.49
▸ PDE4B Q07343 3/20 0.48
▸ PDE4A P27815 2/20 0.48
▸ PDE4C Q08493 2/20 0.48
▸ PDE4D Q08499 2/20 0.48
▸ NPBWR1 P48145 1/20 0.48
▸ MCHR1 Q99705 1/20 0.48
▸ CHEK2 O96017 1/20 0.48
▸ STS P08842 2/20 0.46
▸ CACNB4 O00305 1/20 0.46
▸ CACNA1A O00555 1/20 0.46
▸ CACNA1G O43497 1/20 0.46
▸ CACNG3 O60359 1/20 0.46
▸ CACNA1F O60840 1/20 0.46
▸ CACNA1H O95180 1/20 0.46
▸ CACNB3 P54284 1/20 0.46
▸ CACNA2D1 P54289 1/20 0.46
▸ CACNG7 P62955 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30272608 1.00 GPR119 (0.56) GPR119HRH3ALDH1A1PDE4BPDE4A
SCHEMBL30427283 0.91 GPR119 (0.56) GPR119HRH3ALDH1A1PDE4BPDE4A
SCHEMBL5459344 0.91 GPR119 (0.56) GPR119HRH3ALDH1A1PDE4BPDE4A
SCHEMBL3282383 0.89 GPR119 (0.59) GPR119HRH3NPBWR1MCHR1CHEK2
SCHEMBL21723011 0.88 USP30 (0.44) GPR119ALDH1A1PDE4BCACNB4CACNA1A
SCHEMBL30272628 0.88 USP30 (0.44) GPR119ALDH1A1PDE4BCACNB4CACNA1A
SCHEMBL20570284 0.87 GPR119 (0.57) GPR119HRH3ALDH1A1PDE4BPDE4A
SCHEMBL15536283 0.86 GPR119 (0.67) GPR119HRH3ALDH1A1NPBWR1MCHR1
SCHEMBL29990082 0.86 GPR119 (0.56) GPR119HRH3ALDH1A1PDE4BPDE4A
SCHEMBL27087770 0.86 GPR119 (0.56) GPR119HRH3ALDH1A1PDE4BPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-01-22 — — US disclosed
US-12281124-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors HOFFMANN-LA ROCHE INC. (US) 2025-04-22 — — US disclosed
EP-4474017-A2 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-11 — — EP disclosed
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 — — EP disclosed
EP-3837263-B1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN LA ROCHE (CH) 2024-07-03 — — EP disclosed
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-05-09 — — US disclosed
US-11802133-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors HOFFMANN-LA ROCHE INC. (US) 2023-10-31 — — US disclosed
CN-110678177-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-06-13 — — CN disclosed
US-20230050901-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-02-16 — — US disclosed
US-11149037-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2021-10-19 — — US disclosed
EP-3837263-A1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2021-06-23 — — EP disclosed
CN-112867720-A Novel heterocyclic compounds as monoacylglycerol lipase inhibitors 豪夫迈·罗氏有限公司 2021-05-28 — — CN disclosed
CN-112469724-A Novel heterocyclic compounds as monoacylglycerol lipase inhibitors 豪夫迈·罗氏有限公司 2021-03-09 — — CN disclosed
US-20200308190-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-10-01 — — US disclosed
EP-3634404-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-15 — — EP disclosed
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-03-19 — — US disclosed
WO-2020035425-A1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2020-02-20 — — WO disclosed
WO-2020035424-A1 NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2020-02-20 — — WO disclosed
CN-110678177-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 — — CN disclosed
WO-2018217809-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022130-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LIPA, LPL GPR119 192/4885HRH3 988/4885ALDH1A1 1338/4885
US-12281124-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors LIPC, LPL, MGLL GPR119 53/4885HRH3 2629/4885ALDH1A1 525/4885
US-20240150373-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LPL, MGLL GPR119 53/4885HRH3 2629/4885ALDH1A1 525/4885
US-11149037-B2 Pyrazole MAGL inhibitors MAGI3, MAG, PYM1 GPR119 2756/4885HRH3 3204/4885ALDH1A1 4019/4885
US-20200087304-A1 PYRAZOLE MAGL INHIBITORS MAGI3, MAG, PYM1 GPR119 2756/4885HRH3 3204/4885ALDH1A1 4019/4885
US-20200308190-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, MGLL, LPL GPR119 63/4885HRH3 2444/4885ALDH1A1 651/4885
US-11802133-B2 Heterocyclic compounds as monoacylglycerol lipase inhibitors LIPC, LPL, MGLL GPR119 53/4885HRH3 2629/4885ALDH1A1 525/4885
US-20230050901-A1 HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS LIPC, LPL, MGLL GPR119 53/4885HRH3 2629/4885ALDH1A1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.